Effects of chronic hyperprolactinemia on tuberoinfundibular dopaminergic neurons

Proceedings of the Society for Experimental Biology and Medicine

Volumn 217, Issue 4, 1998, Pages 461-465

  MohanKumar, Puliyur S ^a,b   MohanKumar, Sheba M J ^b   Arbogast, Lydia ^a   Quadri, S Kaleem ^b   Voogt, James L ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PROLACTIN;

ANIMAL CELL; ARCUATE NUCLEUS; ARTICLE; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; HORMONE RESPONSE; HYPERPROLACTINEMIA; IMPLANTATION; MEDIAN EMINENCE; NEUROTRANSMITTER RELEASE; NONHUMAN; RAT; TUBEROHYPOPHYSEAL TRACT;

ANIMALIA;

EID: 0031917121     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-217-44258     Document Type: Article

References (25)

1. ThyagaRajan S, MohanKumar PS, Quadri SK. Cyclic changes in the release of norepinephrine and dopamine in the medial basal hypothalamus: Effects of aging. Brain Res 689:122-128, 1995.
2. MohanKumar PS, ThyagaRajan S, Quadri SK. Tyrosine hydroxylase and dopa decarboxylase activities in the medial preoptic area and arcuate nucleus during the estrous cycle: Effects of aging. Brain Res Bull 42:265-271, 1997.
3. Voogt JL, Arbogast LA, Quadri SK, Andrews GA. Tyrosine hydroxylase messenger RNA in the hypothalamus, substantia nigra, and adrenal medulla of old female rats. Mol Brain Res 8:55-62, 1990.
4. Meites J. Changes in neuroendocrine control of anterior pituitary function during aging. Neuroendocrinology 34:151-156, 1982.
5. Ben-Jonathan N, Arbogast LA, Hyde JF. Neuroendocrine regulation of prolactin release. Prog in Neurobiol 33:399-477, 1989.
6. Arbogast LA, Voogt JL. Hyperprolactinemia increases and hypoprolactinemia decreases tyrosine hydroxylase messenger ribonucleic acid levels in the arcuate nuclei, but not the substantia nigra or zona incerta. Endocrinology 128:997-1005, 1991.
7. Sarkar DK, Gottschall PE, Meites J. Decline in tuberoinfundibular dopaminergic function resulting from chronic hyperprolactinemia in rats. Endocrinology 115:1269-1274, 1984.
8. Simpkins JW, Gabriel SM. Chronic hyperprolactinemia causes progressive changes in hypothalamic dopaminergic and noradrenergic neurons. Brain Res 309:277-282, 1984.
9. Bjorklund A, Flack B, Nobin A, Stenevi U. Organization of the dopamine and noradrenaline innervation of the median eminence-pituitary region in the rat. In: Knowles F, Vollarath L, Eds. Neurosecretion: The Final Neuroendocrine Pathway. New York: Springer-Verlag, p 209, 1974.
10. Arbogast LA, Soares MJ, Robertson MC, Voogt JL. A factor(s) from a trophoblast cell line increases tyrosine hydroxylase activity in fetal hypothalamic cell cultures. Endocrinology 133:111-120, 1993.
11. MohanKumar PS MohanKumar SMJ, Quadri SK, Voogt JL. Chronic hyperprolactinemia and changes in dopamine neurons. Brain Res Bull 42:435-441, 1997.
12. Judd AM, Login IS, Kovacs K, Ross PC, Spangelo BL, Jarvis WD, MacLeod RM. Characterization of the MMQ cell, a prolactin-secreting clonal cell line that is responsive to dopamine. Endocrinology 123:2341-2350, 1988.
13. MohanKumar PS, ThyagaRajan S, Quadri SK. Correlations of catecholamine release in the medial preoptic area with proestrous surges of luteinizing hormone and prolactin: Effects of aging. Endocrinology 135:119-126, 1994.
14. ThyagaRajan S, Meites J, Quadri SK. Underfeeding-induced suppression of mammary tumors: Counteraction by estrogen and haloperidol. Proc Soc Exp Biol Med 203:236-242, 1993.
15. MohanKumar PS, ThyagaRajan S, Quadri SK. Cyclic and age-related changes in norepinephrine concentrations in the medial preoptic area and arcuate nucleus. Brain Res Bull 38:561-564, 1995.
16. ThyagaRajan S, Meites J, Quadri SK. Deprenyl reinitiates estrous cycles, reduces serum prolactin, and decreases the incidence of mammary and pituitary tumors in old acyclic rats. Endocrinology 136:1103-1110, 1995.
17. Demarest KT, Moore KE. Accumulation of L-dopa in the median eminence: An index of tuberoinfundibular dopaminergic nerve activity. Endocrinology 106:463-468, 1980.
18. Moore KE, Demarest KT, Lookingland KJ. Stress, prolactin, and hypothalamic dopaminergic neurons. Neuropharmacology 26:801-808, 1987.
19. Foreman MM, Porter JC. Prolactin augmentation of dopamine and norepinephrine release from supervised medial basal hypothalamic fragments. Endocrinology 108:800-805, 1981.
20. Arita J, Kimura F, Characterization of in vitro dopamine synthesis in the median eminence of rats with haloperidol-induced hyperprolactinemia and bromocriptine-induced hypoprolactinemia. Endocrinology 119:1666-1672, 1986.
21. Gudelsky GA, Moore KE. A comparison of the effects of haloperidol on dopamine turnover in the striatum, olfactory tubercle, and median eminence. J Pharm Exp Ther 202:149-156, 1977.
22. Imperato A, Obinu MC, Carta G, Mascia MS, Casu MA, Dazzi L, Gessa GL. Neuroleptics cause stimulation of dopamine D1 receptors and their desensitization after chronic treatment. Eur J Pharm 264:55-60, 1994.
23. Lane RF, Blaha CD. Chronic haloperidol decreases dopamine release in striatum and nucleus accumbens in vivo: Depolarization block as a possible mechanism of action. Brain Res Bull 18:135-138, 1987.
24. Reiriz J, Ambrosio S, Cobos A, Ballarin M, Tolosa E, Mahy N. Dopaminergic function in rat brain after oral administration of calcium-channel blockers or haloperidol: A microdialysis study. Journal of Neural Transmission General Section 95:195-207, 1994.
25. Cottingham SL, Pickar D, Shimotake TK, Motpied P, Paul SM, Crawley JN. Tyrosine hydroxylase and cholecystokinin mRNA levels in the substantia nigra, ventral tegmental area, and locus ceruleus are unaffected by acute and chronic haloperidol administration. Cell Mol Neurobiol 10:41-50, 1990.